Αποτελέσματα Αναζήτησης
31 Μαρ 2021 · In this review, we aim to assess the prevalence, characteristics, etiology, and outcomes of sepsis in immunocompromised cancer patients and hematopoietic stem cell transplant (HSCT) recipients and to gain knowledge regarding the physiopathology of sepsis in these contexts.
- Outcomes of Sepsis and Septic Shock in Cancer Patients: Focus on ...
Lactate should be used as a biomarker for risk...
- Management of sepsis in neutropenic cancer patients: 2018 guidelines ...
A combination treatment with an aminoglycoside may be...
- Outcomes of Sepsis and Septic Shock in Cancer Patients: Focus on ...
26 Απρ 2021 · Lactate should be used as a biomarker for risk stratification in cancer patients with suspected sepsis. Outcome improvement and better patient stratification could lead to the actualization of ICU admission policies.
15 Απρ 2020 · The risk of sepsis in patients with cancer has been estimated to be 10 times higher than that in patients without cancer, with considerable variations among cancer subtypes . Hematological malignancies, especially acute leukemia and myeloma, exhibit the highest risk of sepsis .
Appropriate empiric antimicrobial therapy for cancer patients with neutropenic sepsis is controversial with monotherapy generally accepted as superior for uncomplicated neutropenic fever, but combination antimicrobial therapy may be superior for those with severe disease.
Beyond sepsis and septic shock, Adrecizumab has the potential to become a platform therapy applicable to a wide range of conditions, in which loss of endothelial barrier integrity plays a role,...
22 Φεβ 2019 · A combination treatment with an aminoglycoside may be considered in neutropenic patients with septic shock (BIII). In case of clinically stabilizing patients or detection of pathogens sensitive to ß-lactam, it is recommended to stop the aminoglycosides (AIII).
Sepsis is a leading cause of mortality in neutropenic cancer patients. Early initiation of effective causative therapy as well as intensive adjunctive therapy is mandatory to improve outcome. We give recommendations for the management of adults with neutropenia and sepsis.
